Research Letter

Title: Regional Difference in Seroprevalence of SARS-CoV-2 in Tokyo: Results from the community point-of-care antibody testing

Authors:

Morihito Takita, MD, PhD[1*], Tomoko Matsumura, MD, PhD[1], Kana Yamamoto MD[1,2,3], Erika Yamashita[2], Kazutaka Hosoda MD[4], Tamae Hamaki MD [2] and Eiji Kusumi MD[1,2]

Affiliations:

[1]Department of Internal Medicine, Navitas Clinic Tachikawa, 3-1-1 Shibasaki 4th floor of Ecute Tachikawa Bldg, Tachikawa, Tokyo, 190-0023, Japan

[2]Department of Internal Medicine, Navitas Clinic Shinjuku, 4-1-6 Shinjuku 7th floor of Newoman Bldg, Shinjuku, Tokyo, 160-0022, Japan

[3]Department of Reproductive, Developmental and Aging Sciences, Graduate School of Medicine, University of Tokyo, 4-6-1 Shirokanedai, Minato, Tokyo, 108-0071, Japan

[4]Department of Pediatrics, Navitas Clinic Tachikawa, Tachikawa, 3-1-1 Shibasaki 4th floor of Ecute Tachikawa Bldg, Tachikawa, Tokyo, 190-0023, Japan

Corresponding Author:

Morihito Takita, MD, PhD

Department of Internal Medicine

Navitas Clinic Tachikawa

Address: 3-1-1 Shibasaki, Ecute Tachikawa 4th floor

Tachikawa, Tokyo, 190-0023, Japan

Phone: +81-42-521-5334

Fax: +81-42-521-5329

Email: takita-ygc@umin.ac.jp

Word Count: 600 words

Abstract

The serosurvey is an alternative way to know the magnitude of the population infected by coronavirus disease 2019 (COVID-19) since the expansion of capacity of the polymerase chain reaction (PCR) to detect the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was delayed. We herein report seroprevalence of COVID-19 accessed in the two community clinics in Tokyo. The point-of-care immunodiagnostic test was implemented to detect the SARS-CoV-2 specific IgG antibody in the peripheral capillary blood. The overall positive percentage of SARS-CoV-2 IgG antibody is 3.83% (95% confidence interval: 2.76-5.16) for the entire cohort (n =1,071). The central Tokyo of 23 special wards exhibited a significantly higher prevalence compared to the other area of Tokyo (p =0.02, 4.68% [95%CI: 3.08-6.79] versus 1.83 [0.68-3.95] in central and suburban Tokyo, respectively). The seroprevalence of the cohort surveyed in this study is low for herd immunity, which suggests the need for robust disease control and prevention. A community-based approach, rather than state or prefectural levels, is of importance to figure out profiles of the SARS-COV-2 outbreak.

Introduction

A current challenge for the measurement of the future outbreak of coronavirus disease 2019 (COVID-19) is to find a more focused or personalized strategy of infection control such as contact tracing until the establishment of the herd immunity by the previous infection or vaccination which is under development.[1] The New York State announced that the seroprevalence in lower-income communities was higher than the overall population (27 versus 20% of positive for IgG of the severe acute respiratory syndrome coronavirus 2, SARS-CoV-2, respectively).[2] We already described our interim analysis of point-of-care antibody testing for COVID-19, conducted in the community clinics in Tokyo, Japan.[3] We herein reported our extensive analysis which showed unique geographical characteristics of seroprevalence of COVID-19 in Tokyo.

Methods

The Institutional Review Board of Navitas Clinic approved the present study (Approval Number: NC2020-01). Asymptomatic subjects have been recruited by web posting of our clinic, and written consent was obtained from all participants prior to the test. The present study here is an observational study analyzing data collected from the medical record. The study participants paid the cost of the point-of-care test since no insurance and public funding was not available to defray it in Japan.

The SARS-CoV-2 specific IgG antibody in the peripheral capillary blood was detected by the point-of-care immunodiagnostic test (SARS-CoV-2 Antibody Testing Kit IgG RF-NC002, Kurabo Industries Ltd, Osaka, Japan) in the two community clinics located in the major railway stations in Tokyo (Navitas Clinic Shinjuku and Tachikawa). The rapid test implemented in this study indicated 76.4, 100 and 94.2% of positive, negative and overall agreement rates, respectively, in accordance with the manufacturer's investigation.

The 95% exact binomial confidential interval (CI) was calculated with the method of Clopper-Pearson using PASS 14 (NCSS, LLC. Kaysville, UT). Statistical significance was considered when two-side p-value <0.05. The descriptive and Fisher's exact test was performed with IBM SPSS Statistics 26 (IBM Corp., Armonk, NY)

Results

The overall positive percentage of SARS-CoV-2 IgG antibody is 3.83% (95% CI: 2.76-5.16) for the entire cohort (n =1,071) (Table 1). No trend of increase in the positive proportion by time was observed (Supplemental Table 1). All participants who had a history of SARS-CoV-2 PCR positive (n =5) showed positive results of IgG, whereas IgG positive was also seen in two with the PCR negative. The seroprevalence in central Tokyo of 23 special wards was significantly

higher than the other area of Tokyo after classification by residence (p =0.02, 4.68% [95%CI: 3.08-6.79] versus 1.83 [0.68-3.95] in central and suburban Tokyo, respectively). Furthermore, we found the regional trend inside the central Tokyo; the highest and lowest prevalence was found in the Southern and Northern areas (7.92% [95%CI: 3.48-15.01] and 0 [0.00-5.13]), respectively, although no statistical significance was observed. (Supplementary Table 2 and Supplementary Figure for classification of regions).

Discussion

The overall seroprevalence in this study is low as the survey in Los Angeles,[4] which suggests that the majority of the population is immunologically naïve for SARS-CoV-2. Naturally, the prevalence is higher in the place with a higher density of population, such as central Tokyo, since the SARS-CoV-2 is primarily transmitted by droplets. The regional trend of seroprevalence is similar to the cumulative number of COVID-19 patients per unit population (Supplementary Table 3). These facts suggest that the community-based investigation would be beneficial to explore the cause of epidemic contagion. Limitation includes the selection bias and accuracy of the test kit. Concerns about the risk of COVID-19 infection such as past fever, illness of cohabitants or co-workers and working environment were common reasons for the participation of this study, which can cause elevation of seroprevalence. Less sensitivity of test kit develops the underestimation of the prevalence. Further serosurvey, along with the fine characterization of population, is warranted for the measurement of a future outbreak.

References

1. Leung K, Wu JT, Liu D, Leung GM. First-wave COVID-19 transmissibility and severity in China outside Hubei after control measures, and second-wave scenario planning: a modelling impact assessment. *Lancet.* 2020;395(10233):1382-1393.

2. New York State. Amid Ongoing COVID-19 Pandemic, Governor Cuomo Announces Phase II Results of Antibody Testing Study Show 14.9% of Population Has COVID-19 Antibodies. https://www.governor.ny.gov/news/amid-ongoing-covid-19-pandemic-governor-cuomo-announces-phase-ii-results-antibody-testing-study. News Release on April 27, 2020. Accessed June 3, 2020.

3. Takita M, Matsumura T, Yamamoto K, et al. Challenges of community point-of-care antibody testing for COVID-19 herd-immunity in Japan. *QJM.* Published online on May 28, 2020. doi: 10.1093/qjmed/hcaa182

4. Sood N, Simon P, Ebner P, et al. Seroprevalence of SARS-CoV-2-Specific Antibodies Among Adults in Los Angeles County, California, on April 10-11, 2020. *JAMA.* Published online on May 18, 2020. doi: 10.1001/jama.2020.8279

Table 1. Characteristics of Study Participants and Proportion with SARS-CoV-2 IgG Positive

Characteristics	Sample size	Proportion of sample, % (95%CI)	No. positive	Proportion positive for SARS-CoV-2 IgG, % (95%CI)
Entire sample	1,071	100	41	3.83 (2.76-5.16)
Sex				
Male	576	53.78 (50.74-56.80)	22	3.82 (2.41-5.73)
Female	495	46.22 (43.20-49.26)	19	3.84 (2.33-5.93)
Age, year				
≤17	13	1.21 (0.65-2.07)	0	0
18-34	134	12.51 (10.59-14.64)	11	8.21 (4.17-14.21)
35-54	653	60.97 (57.98-63.91)	19	2.91 (1.76-4.51)
≥55	271	25.30 (22.72-28.02)	11	4.06 (2.04-7.15)
Episodes of fever after Dec 2019	332	31.00 (28.24-33.87)	19	5.72 (3.48-8.79)
History of PCR test for SARS-CoV-2	45	4.20 (3.08-5.58)	7	15.56 (6.49-29.46)
PCR *positive*	5	0.47 (0.15-1.09)	5	100
PCR *negative*	40	3.73 (2.68-5.05)	2	5.00 (0.61-16.92)
Cohabitant diagnosed with COVID-19	9	0.84 (0.38-1.59)	4	44.44 (13.70-78.80)
Healthcare worker	175	16.34 (14.17-18.69)	7	4.00 (1.62-8.07)
Residence				
Central Tokyo; 23 special wards	565	52.75 (49.71-55.78)	27	4.78 (3.17-6.88)
Suburban Tokyo	317	29.60 (26.88-32.43)	5	1.58 (0.51-3.64)
Neighboring prefectures of Tokyo	173	16.15 (14.00-18.50)	9	5.20 (2.41-9.65)
Other	16	1.49 (0.86-2.41)	0	0

Neighboring prefectures of Tokyo include Kanagawa, Saitama, Chiba and Yamanashi Prefectures.